Page 1 of Clinical Trials for Biological Campath-1h, 95 Total Matches

Show/Hide Clinical Trials Which are Not Seeking New Volunteers

1
Completed
Fludarabine and Alemtuzumab or Cyclophosphamide Followed by Peripheral Blood Stem Cell Transplant or Alemtuzumab in Treating Patients With Advanced or Progressive Chronic Lymphocytic Leukemia
Last Updated: November 22, 2011
Condition(s): Leukemia
2
Recruiting
Imprime PGG, Alemtuzumab, and Rituximab in Treating Patients With High Risk Chronic Lymphocytic Leukemia
Last Updated: April 18, 2012
Condition(s): B-cell Chronic Lymphocytic Leukemia; Refractory Chronic Lymphocytic Leukemia; Stage 0 Chronic Lymphocytic Leukemia; Stage I Chronic Lymphocytic Leukemia; Stage II Chronic Lymphocytic Leukemia
3
Completed
Fludarabine, Cyclophosphamide, and Rituximab or Alemtuzumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia
Last Updated: May 10, 2011
Condition(s): Leukemia
4
Recruiting
T-cell Recovery in Patients With Leukemia, Advanced Lymphoma, Myelodysplastic Syndrome, or Myeloproliferative Disorder Receiving Alemtuzumab and Undergoing Donor Stem Cell Transplant
Last Updated: May 12, 2011
Condition(s): Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms
5
Recruiting
T-Reg Cell Kinetics for Patients Receiving Stem Cell Transplant
Last Updated: April 10, 2012
Condition(s): Leukemia; Hodgkin Lymphoma; Non Hodgkin Lymphoma; Myeloproliferative Disorders
6
Withdrawn
R-CHOP and Alemtuzumab in Patients With Chronic Lymphocytic Leukemia
Last Updated: December 28, 2011
Condition(s): Chronic Lymphocytic Leukaemia; Patients Resistant to a Purine Analogous; Patients Relapsed With Purines Therapy
7
Recruiting
Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System
Last Updated: March 14, 2012
Condition(s): Myelodysplastic Syndrome; Hodgkin's Lymphoma; Non-Hodgkin's Disease; Acute Leukemia; Multiple Myeloma
8
Active, not recruiting
CHOP and Campath-1H in Previously Untreated Aggressive T/NK-Cell Lymphomas
Last Updated: November 16, 2011
Condition(s): Non-Hodgkin's Lymphoma
9
Active, not recruiting
Subcutaneous Alemtuzumab Combined With Oral Dexamethasone, Followed by Alemtuzumab Maintenance or Allo-SCT in CLL With 17p- or Refractory to Fludarabine
Last Updated: March 9, 2012
Condition(s): Chronic Lymphocytic Leukemia
10
Completed
Study to Evaluate the Combination of Fludarabine, Cyclophosphamide, and Alemtuzumab in Patients With B-cell Chronic Lymphatic Leukemia (B-CLL)
Last Updated: January 26, 2010
Condition(s): B-cell Chronic Lymphocytic Leukemia
11
Recruiting
Pentostatin, Cyclophosphamide, and Rituximab Followed By Alemtuzumab in Treating Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia
Last Updated: April 6, 2011
Condition(s): Leukemia
12
Completed
Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two
Last Updated: January 30, 2012
Condition(s): Multiple Sclerosis, Relapsing-Remitting
13
Active, not recruiting
Rituximab, Alemtuzumab, and GM-CSF As First-Line Therapy in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia
Last Updated: April 11, 2012
Condition(s): Leukemia
14
Active, not recruiting
A Phase II Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Rebif® in Patients With Early, Active Relapsing-Remitting Multiple Sclerosis
Last Updated: July 13, 2009
Condition(s): Multiple Sclerosis, Relapsing-Remitting
15
Completed
Subcutaneous Alemtuzumab (CAMPATH®, MabCampath®) in Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia
Last Updated: February 29, 2012
Condition(s): B-Cell Chronic Lymphocytic Leukemia (B-CLL)
16
Recruiting
Pentostatin, Alemtuzumab, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Last Updated: September 16, 2010
Condition(s): Leukemia; Lymphoma
17
Active, not recruiting
A Phase II Trial of Alemtuzumab and Rituximab in Patients With Previously Untreated CLL
Last Updated: April 14, 2011
Condition(s): Leukemia
18
Completed
Fludarabine (Fludara®) Plus Alemtuzumab (CAMPATH®, MabCampath®) vs Fludarabine Alone in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients
Last Updated: July 18, 2011
Condition(s): B-Cell Chronic Lymphocytic Leukemia
19
Active, not recruiting
Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer
Last Updated: January 30, 2012
Condition(s): Acute Undifferentiated Leukemia; Adult Acute Lymphoblastic Leukemia in Remission; Adult Acute Myeloid Leukemia in Remission; Atypical Chronic Myeloid Leukemia, BCR-ABL Negative; Burkitt Lymphoma; Childhood Acute Lymphoblastic Leukemia in Remission; Childhood Acute Myeloid Leukemia in Remission; Childhood Chronic Myelogenous Leukemia; Childhood Diffuse Large Cell Lymphoma; Childhood Immunoblastic Large Cell Lymphoma; Childhood Myelodysplastic Syndromes; Chronic Myelomonocytic Leukemia; Chronic Phase Chronic Myelogenous Leukemia; Cutaneous B-cell Non-Hodgkin Lymphoma; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Intraocular Lymphoma; Juvenile Myelomonocytic Leukemia; Mast Cell Leukemia; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Nodal Marginal Zone B-cell Lymphoma; Previously Treated Myelodysplastic Syndromes; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute Myeloid Leukemia; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Childhood Acute Lymphoblastic Leukemia; Recurrent Childhood Acute Myeloid Leukemia; Recurrent Childhood Large Cell Lymphoma; Recurrent Childhood Lymphoblastic Lymphoma; Recurrent Childhood Small Noncleaved Cell Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Small Lymphocytic Lymphoma; Recurrent/Refractory Childhood Hodgkin Lymphoma; Refractory Chronic Lymphocytic Leukemia; Refractory Multiple Myeloma; Relapsing Chronic Myelogenous Leukemia; Secondary Myelodysplastic Syndromes; Splenic Marginal Zone Lymphoma; Testicular Lymphoma; Waldenstrom Macroglobulinemia
20
Recruiting
Alemtuzumab-Ofatumumab in Previously Untreated Symptomatic Chronic Lymphocytic Leukemia
Last Updated: August 11, 2011
Condition(s): Stage I Chronic Lymphocytic Leukemia; Stage II Chronic Lymphocytic Leukemia; Stage III Chronic Lymphocytic Leukemia; Stage IV Chronic Lymphocytic Leukemia

Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.

The URL of this page is: http://clinicaltrialsfeeds.org/clinical-trials/results/?term=Biological+Campath-1h

Page 1 of Clinical Trials for Biological Campath-1h, 95 Total Matches

Get the Latest Results via Email or RSS

Subscribe via Web Newsreaders

Browse

Clinical Trials Background

About